Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06184516 · ClinicalTrials.gov registry record · Phase 2
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
A Phase 2 study of Urothelial Carcinoma Bladder, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 1
- Study location
NCT06184516 is a Phase 2 study of Urothelial Carcinoma Bladder that is actively recruiting participants, run by University of Florida. The registered enrollment target is 147 participants, above the 87-participant average among 16 other Urothelial Carcinoma Bladder trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06184516, a Phase 2 study of Urothelial Carcinoma Bladder, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.
Conditions Studied
Interventions
- PROCEDURE Radical cystectomy
- PROCEDURE Reproductive organ sparing radical cystectomy
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06184516
The ClinicalTrials.gov registry entry for NCT06184516 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 16 other Urothelial Carcinoma Bladder trials with a reported enrollment target (69% higher). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma Bladder appearing as the primary indexed condition, and to 2 interventions - of which Radical cystectomy is the first listed.
NCT06184516 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06184516 about?
NCT06184516 is a clinical study titled "Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy". Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in ...
What is the current status of trial NCT06184516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2024-08-30. Estimated completion is 2028-03.
What conditions does trial NCT06184516 study?
This clinical trial studies the following conditions: Urothelial Carcinoma Bladder.
What interventions are being tested in trial NCT06184516?
The interventions under investigation include: Radical cystectomy (PROCEDURE), Reproductive organ sparing radical cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT06184516?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06184516 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Renal Retention in High Grade Upper Tract Urothelial Cancer
RECRUITING · Phase 2
-
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
ACTIVE NOT RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.